Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial. (nature.com)

Authors: Long GV … Tawbi H Journal: Nature Medicine Published: 2026-10-24 DOI: https://doi.org/10.1038/s41591-026-04756-1